Metformin, SGLT2i, GLP1-RA, and other antidiabetic drugs, by targeting some biological mechanisms, e.g., oxidative stress and mitochondrial dysfunction, demonstrated antioxidant and ROS scavenger properties in in vitro and in vivo models, a common feature of prediabetes and CRC [191,192]. The gene discussed is GLP1R; the disease is colorectal carcinoma.